Truist Financial Lowers Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00

Autolus Therapeutics (NASDAQ:AUTL) had its price target reduced by Truist Financial from $11.00 to $10.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other equities analysts have also commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Wells Fargo & Company decreased their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.32.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $1.55 on Tuesday. Autolus Therapeutics has a 52 week low of $1.52 and a 52 week high of $6.31. The firm’s 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $2.80. The firm has a market cap of $412.45 million, a price-to-earnings ratio of -1.28 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. Analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares during the period. FMR LLC lifted its position in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares during the period. Candriam S.C.A. bought a new stake in Autolus Therapeutics during the fourth quarter worth about $7,500,000. AXA S.A. purchased a new stake in Autolus Therapeutics in the fourth quarter worth about $4,288,000. Finally, Millennium Management LLC increased its stake in shares of Autolus Therapeutics by 91.6% during the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock valued at $3,885,000 after purchasing an additional 790,437 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.